Heraldnet.com
SUNDAY, JULY 5, 2009 4:34 pm
LocalNorthwestNation & WorldPoliticsSpecial ReportsPhotosColumnistsMultimedia 
Blog
Michelle Dunlop
Tests continue on Boeing's 787
Your town news
Mike Benbow
Business editor Mike Benbow's insights into all things business.
•Latest: State's new commerce director shares his business principles
Steve Tytler
Steve Tytler answers your questions about real estate.
•Latest: Landlords should read up before they rent out
 
WEEK IN REVIEW
Saturday


Fireworks blamed in Marysville house fire
Sailors for a day: Naval Station Everett opens ...
Edmonds backs off red-light cameras
Friday
Armed man shot by deputies in Arlington
Police ID make of vehicle in fatal hit-and-run
Boeing's 6-month tally: 1 net order
Thursday


One fire rips through $2 million home, another ...
Swine flu claims 2nd victim in Snohomish County
Jetty Island firefight continues; hot weather ...
Wednesday


Fire District 1 negotiates to take over service...
Snohomish County population rising fast since 2...
Honey's owners indicted by feds
Tuesday


Mobile home tenants along Snohomish River told ...
Lincoln to leave Everett in 2013
Put on your sailor's cap and explore Naval Stat...
Monday


Disabled people will be left without a ride
You'll soon have 4,500 reasons to trade in that...
Pay hike deserved, Monroe chief says
Sunday


1,670 local students in county are without homes
Monroe's business gets done in secret
$9 million to be sought for U.S. 2 in federal t...
 

ADVERTISEMENT

Business   Print This Article  Email This Page  Subscribe Now! facebook digg reddit del.icio.us fark stumble

 
ADVERTISEMENT

 
CONTACT THE HERALD
Mike Benbow, Business Editor
benbow@heraldnet.com
 
Published: Thursday, November 20, 2008

Nasdaq to de-list Lumera of Bothell

BOTHELL -- Lumera Corp. is expected to be removed from the Nasdaq Global Market listing because of its dwindling assets, the Bothell-based firm said Wednesday.

Nasdaq decided on the move because the firm doesn't have a minimum stockholders' equity of $10 million to stay on the listing, according to Lumera. Stockholders' equity, or the book value of a company, represents a company's total assets minus its total liabilities.

For the quarter that ended Sept. 30, the company's stockholders' equity was about $8.72 million. That still enables the company to stay on the Nasdaq Capital Market listing, said Helene Jaillet, director of investor relations and corporate communications for Lumera.

Lumera is trying to have Nasdaq delay the action until the company decides on its merger with GigOptix LLC, a private firm in Palo Alto, Calif., Jaillet said.

"If the merger is approved, we will meet the listing requirement," Jaillet said.

The company's shareholders are expected to decide on the merger Dec. 4, Jaillet said.

Lumera shares on Wednesday closed at 30 cents, down 1 cent, or 3.2 percent. The company's shares were above $2 before it announced the proposed merger in March, Jaillet said. Since then, its shares have tumbled.

"What hurt us is we are very restricted in what we can say" about the merger, she said.

Lumera, a spinoff of Microvision Inc., designs electro-optic components based on proprietary polymer compounds for the telecommunications and computing industries.

The ongoing declines of Lumera shares don't surprise Tim Raetzloff, an Edmonds businessman who monitors local companies' stocks. Raetzloff created the Abarim Snohomish County Stock Index, which lists 10 local publicly traded firms. The index only lists companies whose share price is $1 a share or higher.

Companies such as Lumera require long-term investments to develop products and put them on the market, Raetzloff said. They are struggling to attract investors in the current volatile market.

It's a bad time for most businesses no matter what industry they are in, Raetzloff said. The Abarim Snohomish County Stock Index on Wednesday closed at its lowest point since Jan. 16, 1996.

Two bio-tech firms listed on the index are OncoGenex Pharmaceuticals Inc. and Seattle Genetics Inc., both of which are based in Bothell. OncoGenex shares ended at $2.40, down 25 cents, or 9.43 percent for the day. Seattle Genetics' shares closed at $9.38, down 66 cents, or 6.57 percent. Seattle Genetics is faring well because it is close to obtaining government approval for its drugs to hit the market, Raetzloff said.

Reporter Yoshiaki Nohara: 425-339-3029 or ynohara@heraldnet.com.

READER COMMENTS
Be the first to comment.
You must be a registered user and verify your e-mail address to post comments to blogs or articles on HeraldNet.

To register, click here. To read other terms and conditions, click hereLog out

1. Waves wash away Explosion's title hopes
2. You've got your pick of Fourth of July fun
3. Snohomish entrepreneur bounces back with new venture
4. Inslee downplays fears Boeing will send second 787 line elsewhere
5. Popular park changing hands
6. Deputies shoot armed man near Arlington
7. Why, governor?
8. Edmonds backs off red-light cameras
9. Vehicle that killed girl was Chevy Astro minivan
10. Arlington buys up more water rights
Enterprise Newspaper Snohomish County Business Journal
Warriors looking for balance
Three Scots vying for QB slot
Jackson looks for another title
Decorated veteran continues to serve as active volunteer
City Council reviewing sign regulations
Wildcats get a peek at newcomers
Lynnwood still in rebuilding mode
Shoreline feels a kindergarten growth spurt
Leave the patriotic pyrotechnics to professionals, cities urge
The Enterprise Online Newspaper

TODAY'S TOP JOBS
 View All Top Jobs 
Top Cars
Top Homes


ADVERTISEMENT